Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset - HMS LINCS Database

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)

Download: Excel (XLSX), Comma-separated (CSV)

Filter results: >>>>

|<
<<
Previous
Page 3 of 18
Next
>>
>
51 to 75 of 432 records
per page:

Cell line	Drug name	Experimental replicate	Timepoint	Curve type (GR values)	Curve type (relative cell counts)	Experiment name	Number of concentrations	Cell doublings (DMSO control)	GR50	GRmax	GR_AOC	GEC50	GRinf	Hill slope (GR values)	R-squared sigmoid fit (GR values)	P-value sigmoid fit (GR values)	R-squared flat fit (GR values)	IC50	Emax	AUC	EC50	Einf	Hill slope (relative cell counts)	R-squared sigmoid fit (relative cell counts)	P-value sigmoid fit (relative cell counts)	R-squared flat fit (relative cell counts)
BT-20	AZD-6482	2	72	sigmoid	sigmoid	BT20 AZD6482 0 2 72	8	1.645	0.581	0.0253	0.303	3.86	-1.0	0.58	0.904	0.000884	NA	1.34	0.333	0.772	1.34	0.0	0.582	0.864	0.0025	NA
BT-20	TGX221	2	72	flat	flat	BT20 TGX-221 0 2 72	8	1.656	Inf	1.0	0.0477	0.0	1.0	0.01	-0.101	1.0	0.946	Inf	1.0	0.961	0.0	1.0	0.01	-0.101	1.0	0.956
BT-20	GDC-0980	2	72	sigmoid	sigmoid	BT20 apitolisib 0 2 72	8	1.659	0.0456	-0.414	0.639	0.0629	-0.33	1.58	0.993	4.18e-07	NA	0.0641	0.131	0.575	0.0506	0.168	1.74	0.995	1.2e-07	NA
BT-549	WYE-125132	3	72	sigmoid	sigmoid	BT549 WYE-132 0 3 72	8	1.662	0.0271	0.0265	0.567	0.0245	0.0525	1.1	0.992	5.72e-07	NA	0.0574	0.33	0.592	0.0203	0.345	1.13	0.991	6.54e-07	NA
HCC70	WYE-125132	2	72	sigmoid	sigmoid	HCC70 WYE-132 0 2 72	8	1.675	0.213	0.471	0.332	0.0211	0.467	1.18	0.996	6.89e-08	NA	Inf	0.598	0.744	0.0194	0.595	1.17	0.996	7.52e-08	NA
HCC70	GDC-0980	2	72	sigmoid	sigmoid	HCC70 apitolisib 0 2 72	8	1.676	0.318	-0.0849	0.284	0.451	-0.205	0.983	0.976	1.34e-05	NA	0.536	0.27	0.795	0.285	0.252	1.11	0.972	2.28e-05	NA
HCC70	Dactolisib	2	72	sigmoid	sigmoid	HCC70 dactolisib 0 2 72	8	1.677	0.312	0.238	0.341	0.195	0.103	0.493	0.954	9.66e-05	NA	2.24	0.447	0.738	0.0858	0.419	0.56	0.954	9.8e-05	NA
HCC70	Omipalisib	2	72	sigmoid	sigmoid	HCC70 omipalisib 0 2 72	8	1.682	0.00746	-0.705	1.01	0.0241	-0.703	0.749	0.991	6.69e-07	NA	0.0135	0.0399	0.359	0.0121	0.0458	0.852	0.989	1.45e-06	NA
HCC70	KIN001-244	2	72	flat	flat	HCC70 KIN001-244 0 2 72	8	1.684	Inf	0.898	-0.0201	0.0	0.898	0.01	0.508	0.119	1.01	Inf	0.916	1.02	0.0	0.916	0.01	-0.0458	1.0	1.01
BT-549	MK2206	3	72	sigmoid	sigmoid	BT549 MK-2206 0 3 72	8	1.685	Inf	0.714	0.131	0.123	0.711	3.44	0.953	0.000102	NA	Inf	0.771	0.895	0.123	0.768	3.25	0.949	0.000136	NA
HCC38	Torin1	1	72	sigmoid	sigmoid	HCC38 Torin1 0 1 72	8	1.688	0.0287	-0.0113	0.569	0.0278	0.013	0.843	0.993	4.14e-07	NA	0.0653	0.304	0.585	0.0204	0.325	0.9	0.992	4.53e-07	NA
HCC70	MK2206	2	72	sigmoid	sigmoid	HCC70 MK-2206 0 2 72	8	1.690	0.446	0.244	0.2	0.301	0.226	1.53	0.973	1.92e-05	NA	1.03	0.448	0.851	0.266	0.44	1.56	0.965	4.11e-05	NA
BT-20	Alpelisib	2	72	sigmoid	sigmoid	BT20 alpelisib 0 2 72	8	1.692	0.253	-0.0994	0.405	2.25	-1.0	0.503	0.835	0.00451	NA	0.612	0.259	0.698	0.612	0.0	0.507	0.764	0.0131	NA
HCC70	BX-912	2	72	sigmoid	sigmoid	HCC70 BX-912 0 2 72	8	1.693	1.25	0.00257	0.0619	1.25	-0.00649	5.0	0.971	2.55e-05	NA	1.44	0.311	0.961	1.2	0.306	5.0	0.956	8.35e-05	NA
HCC38	Everolimus	1	72	sigmoid	flat	HCC38 everolimus 0 1 72	8	1.703	11.8	0.54	0.428	0.000126	0.341	0.1	0.688	0.0303	NA	Inf	0.641	0.664	0.0	0.641	0.01	0.571	0.0788	0.665
BT-549	Sirolimus	3	72	flat	flat	BT549 rapamycin 0 3 72	8	1.703	Inf	0.455	0.482	0.0	0.455	0.01	0.376	0.243	0.518	Inf	0.582	0.626	0.0	0.582	0.01	0.436	0.179	0.625
HCC70	PIK-93	2	72	sigmoid	sigmoid	HCC70 PIK-93 0 2 72	8	1.705	4.34	0.647	0.0132	9.3	-1.0	1.44	0.888	0.0014	NA	6.01	0.718	0.991	6.01	0.0	1.49	0.872	0.00208	NA
HCC38	WYE-125132	1	72	sigmoid	sigmoid	HCC38 WYE-132 0 1 72	8	1.708	0.0604	0.142	0.447	0.0481	0.134	1.36	0.997	3.43e-08	NA	0.115	0.384	0.669	0.0413	0.381	1.4	0.996	6.46e-08	NA
BT-20	Omipalisib	2	72	sigmoid	sigmoid	BT20 omipalisib 0 2 72	8	1.717	0.00324	-0.799	1.1	0.00361	-0.354	4.99	0.808	0.00704	NA	0.00518	0.0194	0.291	0.00429	0.111	1.34	0.968	3.16e-05	NA
HCC70	Trametinib	2	72	sigmoid	sigmoid	HCC70 trametinib 0 2 72	8	1.721	0.506	0.504	0.395	0.00469	0.467	0.581	0.944	0.000179	NA	Inf	0.612	0.687	0.00389	0.585	0.57	0.948	0.000138	NA
BT-20	Trametinib	2	72	sigmoid	sigmoid	BT20 trametinib 0 2 72	8	1.723	0.761	0.303	0.289	11.1	-0.768	0.347	0.965	4.13e-05	NA	2.56	0.478	0.77	2.56	0.0	0.362	0.957	8.16e-05	NA
HCC38	Sirolimus	1	72	flat	flat	HCC38 rapamycin 0 1 72	8	1.723	Inf	0.531	0.429	0.0	0.531	0.01	0.623	0.0538	0.573	Inf	0.631	0.66	0.0	0.631	0.01	0.536	0.0998	0.661
HCC38	CAL-101	1	72	sigmoid	sigmoid	HCC38 idelalisib 0 1 72	8	1.723	Inf	0.92	0.00328	1.18	0.903	1.47	0.768	0.0125	NA	Inf	0.932	0.997	1.16	0.918	1.48	0.763	0.0133	NA
HCC70	Buparlisib	2	72	sigmoid	sigmoid	HCC70 buparlisib 0 2 72	8	1.724	0.861	-0.272	0.162	1.33	-0.556	1.71	0.989	1.21e-06	NA	1.12	0.175	0.888	1.03	0.0639	1.76	0.982	5.47e-06	NA
HCC70	AZD8055	2	72	sigmoid	sigmoid	HCC70 AZD8055 0 2 72	8	1.724	0.17	0.404	0.346	0.0331	0.385	0.897	0.996	7.36e-08	NA	Inf	0.543	0.728	0.0284	0.531	0.905	0.996	6.22e-08	NA

|<
<<
Previous
Page 3 of 18
Next
>>
>
51 to 75 of 432 records
per page:

HMS LINCS Project

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)